Xspray Pharma AB (publ)
Nasdaq Stockholm · LEI 549300NGRQCNZ3X4L157· Fiscal year 2025
Staff cost per employee
Not disclosed
Employees
Not disclosed
Quick read
- Operating loss of $15.4M in 2025.
Last 3 years
Revenue
Operating income
See the share price on Google Finance ↗
Investor metrics
2025
- ROE
- -28.4%
- Debt-to-equity
- 27.2%
- Equity ratio
- 78.6%